In light of the large number of studies published since the 2004 update of Schizophrenia
Patient Outcomes Research Team psychopharmacological treatment recommendations, we …

The introduction of second-generation antipsychotics and cognitive therapies for
schizophrenia over the past two decades generated considerable optimism about …

Background Clozapine is an atypical antipsychotic demonstrated to be superior in the
treatment of refractory schizophrenia which causes fewer movement disorders. Clozapine …

Despite treatment advances over the past decades, schizophrenia remains one of the most
severe psychiatric disorders that is associated with a chronic relapsing course and marked …

Background In many countries of the industrialised world second generation (" atypical")
antipsychotics have become the first line drug treatment for people with schizophrenia. The …

Clozapine is, in most countries, underutilized and the initiation of clozapine is often delayed.
The purpose of this study is to investigate the reasons for the delay and the underutilization …

Despite pharmacologic advances, the treatment of schizophrenia remains a challenge, and
suboptimal outcomes are still all too frequent. Although treatment goals of response …

Antipsychotic polypharmacy and high doses have been associated with poorer outcome,
longer hospital stays, and increased side effects. The present naturalistic study assessed the …

In general, rigorous data on combination therapy in schizophrenia are rare and further
randomized controlled trials, naturalistic trials and head-to-head-trials are necessary. Some …

Introduction: Clozapine, a poorly tolerated antipsychotic drug, is widely recognized as the
only efficacious option in treatment-resistant psychosis. The United Kingdom (UK) National …